Vivos Inc. Reports Unprecedented Growth in Animal Cancer Care
The journey of Vivos Inc. (OTCQB: RDGL), a frontrunner in cutting-edge oncology solutions for pets, has taken a remarkable turn. The company revealed record-setting figures for its IsoPet® division, focused on innovative animal cancer treatments, during an impressive first quarter. With a staggering 150% increase in the volume of treatments compared to the previous year, this achievement underscores the significance of IsoPet® in transforming veterinary care.
Exciting Developments in Q1 2025
One of the most notable highlights for Vivos Inc. in the first quarter of this year is the considerable surge in treatment volumes. A total of 15 pets received IsoPet® therapy, showcasing the therapeutic potential of its patented Precision Radionuclide Therapy™ (PRnT™). These treatments are scheduled biweekly, ensuring an uninterrupted supply of yttrium-90 (Y-90) hydrogel, which is crucial for accurate and localized radiation treatment.
Recent Treatment Successes
The advancements are evident, as recent activities included successful treatment of pets in regions like New Jersey and Texas. Certified clinics, such as NorthStar Vets and Brazos Equine Hospital, provided treatments that minimize stress for pets and their owners. This outpatient approach not only facilitates a better experience for the animals but also demonstrates a considerable reduction in tumors and enhancements in the pets’ overall well-being.
Innovative Applications in Veterinary Oncology
Vivos Inc. is not just resting on its laurels; it is continuously pushing the boundaries of veterinary oncology. The company has successfully ventured into equine oncology, treating horses with challenging conditions like ocular squamous cell carcinoma (SCC). This groundbreaking approach, featuring direct cornea injections, has paved the way for new possibilities in treating conditions previously thought to be difficult to manage. Not only has IsoPet® provided palliative care, but it has also supported recovery after tumor removal, enhancing the prognosis for equine patients.
Expanding Access to Innovative Therapies
The growth of Vivos Inc. includes increasing the number of clinics offering IsoPet® treatments. As of this quarter, 14 certified clinics are available to serve both small animals and equine patients. The addition of facilities like Brazos Equine Hospital and Sumner Veterinary Hospital aims to ensure that more pet owners have convenient access to these groundbreaking therapies across the country. The initiative demonstrates a commitment to providing a broader reach for innovative cancer treatments, significantly improving access for pet owners.
Engaging Communities and Marketing Initiatives
Vivos Inc. has been proactive in amplifying its presence in the veterinary community through strategic marketing efforts. With a strong presence at major veterinary conferences, including VMX and WVC, the company is keen on promoting greater awareness of IsoPet® therapies. Additionally, targeted newsletters and interactive social media campaigns are contributing to an uptick in inquiries related to treatments, showcasing community support and enthusiasm for these non-surgical interventions.
Positioning in a Growing Market
The demand for veterinary oncology is escalating, aligned with a significant market valuation reaching $1.18 billion in recent years. The rise in diagnoses of cancer-related conditions among dogs, cats, and other animals has put IsoPet® at the forefront as a viable, non-invasive alternative. With part of the treatment costs covered by select pet insurance plans, the approach not only caters to the medical needs but also addresses financial concerns of pet owners, thus fostering a friendly and affordable option in treatment.
Leadership Insights
Dr. Michael K. Korenko, the President and CEO of Vivos Inc., shared his enthusiasm about the company's achievements, stating, "IsoPet® is changing the landscape of veterinary oncology. Our results from this quarter reflect significant growth and potential for future applications, driven by positive feedback from both veterinarians and pet owners." His vision for the company emphasizes expanding access to therapies and exploring strategic partnerships to bolster the division’s growth.
About IsoPet®
IsoPet® is recognized as a cutting-edge, non-invasive therapy option that delivers precise, high-dose beta radiation to solid tumors using Y-90 hydrogel. This innovative approach is suitable for a variety of animals, including cats, dogs, horses, and even exotic pets, effectively targeting various forms of cancer. Continuous education and certification for veterinarians play a critical role in ensuring the treatment's safety and efficacy.
Frequently Asked Questions
What is IsoPet®?
IsoPet® is a non-invasive therapy that utilizes Y-90 hydrogel to treat solid tumors in various animals, including pets and equines.
How does IsoPet® therapy work?
The therapy delivers high-dose beta radiation directly to tumors, which minimizes impact on adjacent healthy tissues, ensuring a safer treatment experience.
What were the significant achievements for Vivos Inc. in Q1 2025?
Vivos Inc. reported a 150% increase in treatment volume for IsoPet®, treating a total of 15 pets, alongside expanding clinic availability.
How many clinics offer IsoPet® treatments currently?
There are currently 14 certified clinics offering IsoPet® treatments, with plans for further expansion to provide broader access.
What are the future plans for IsoPet®?
The company aims to explore new applications of IsoPet® and to further enhance accessibility, making innovative treatments available to more pet owners across the country.
